ADHD News Headlines
VYVANSE Demonstrated Significant Improvement In ADHD Symptoms In Adults
Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, presented the results of a phase III pivotal study in which VYVANSE demonstrated significant improvements in Attention Deficit Hyperactivity Disorder (ADHD) symptoms in adults and met all safety and efficacy endpoints. "Adults with ADHD often find it challenging to focus and organize during the day.
Shire Investigational Nonstimulant INTUNIV Showed Significant Efficacy In Reducing ADHD Symptoms
Shire plc(LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, has presented at a major scientific meeting findings from analyses of pivotal trial results of INTUNIV, a selective alpha-2A-agonist. This compound is an investigational once-daily medication, which is being evaluated for the treatment of the symptoms of Attention Deficit Hyperactivity Disorder (ADHD).
Shire's Investigational Nonstimulant ADHD Treatment INTUNIV(TM) Demonstrated Significant Efficacy In Reducing ADHD Symptoms
Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, presented at a major scientific meeting findings from analyses of pivotal trial results of INTUNIV, a selective alpha-2A-agonist. This compound is an investigational once-daily medication, which is being evaluated for the treatment of the symptoms of Attention Deficit Hyperactivity Disorder (ADHD).
New Analysis In Boys And Girls Shows The ADHD Patch, DAYTRANA(TM), Offered ADHD Symptom Control For 12 Months
Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announced findings from a new data analysis that was conducted to examine treatment differences with DAYTRANA™ (methylphenidate transdermal system) between boys and girls aged 6 to 12 years with Attention Deficit Hyperactivity Disorder (ADHD).
OROS(R) Methylphenidate In Adults With ADHD: New Insights
Although once considered to be a disorder only seen in children, Attention Deficit Hyperactivity Disorder (ADHD) is now known to be a condition associated with a wide range of functional impairments throughout the lifespan(1). In the US, the overall prevalence of ADHD in adults is estimated to range between 3.4% and 4.4%(2), and between 30 and 70% of children with ADHD continue to exhibit symptoms into adult years(3).
New Analysis In Boys And Girls Shows The ADHD Patch, DAYTRANA(TM) (methylphenidate Transdermal System), Offered ADHD Symptom Control For 12 Months
Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, announced findings from a new data analysis that was conducted to examine treatment differences with DAYTRANA(TM) (methylphenidate transdermal system) between boys and girls aged 6 to 12 years with Attention Deficit Hyperactivity Disorder (ADHD).
Shire To Present Additional Scientific Data On ADHD Treatment Portfolio At American Psychiatric Association Annual Meeting
Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announced today that it will present key scientific data on its Attention Deficit Hyperactivity Disorder (ADHD) treatments, lisdexamfetamine dimesylate, methylphenidate transdermal system and the investigational non-stimulant treatment under FDA review, guanfacine extended release, at the American Psychiatric Association (APA) annual meeting to be held May 3rd to 8th in Washington, D.C.
Shire To Present Additional Scientific Data On ADHD Treatment Portfolio At American Psychiatric Association Annual Meeting
Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, announced today that it will present key scientific data on its Attention Deficit Hyperactivity Disorder (ADHD) treatments, lisdexamfetamine dimesylate, methylphenidate transdermal system and the investigational non-stimulant treatment under FDA review, guanfacine extended release, at the American Psychiatric Association (APA) annual meeting to be held May 3rd to 8th in Washington, D.C.
Sensory Treatment Reduces Autistic Mannerisms
Parents of children with autism are increasingly turning to sensory integration treatment to help their children deal with the disorder, and they're seeing good results. In 2007, 71 percent of parents who pursued alternatives to traditional treatment used sensory integration methods, and 91 percent found these methods helpful.
Simplicity Of Working Memory Study Could Help With ADD And Other Attention Difficulties
A mind is a terrible thing to waste, but humans may have even less to work with than previously thought. University of Missouri researchers found that the average person can keep just three or four things in their "working memory" or conscious mind at one time. This finding may lead to better ways to assess and help people with attention-deficit and focus difficulties, improve classroom performance and enhance test scores.
FDA Approves VYVANSE(TM) (lisdexamfetamine Dimesylate), The First And Only Once-Daily Prodrug Stimulant To Treat ADHD In Adults
Shire plc (LSE: SHP) (NASDAQ: SHPGY,), the global specialty biopharmaceutical company, announced that it has received approval from the U.S. Food and Drug Administration (FDA) for VYVANSE(TM) (lisdexamfetamine dimesylate), for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adults.
Heart Tests Should Be Carried Out Before Treatment With Stimulant Drugs For Children With ADHD
Children with attention deficit hyperactivity disorder (ADHD) should get careful cardiac evaluation and monitoring - including an electrocardiogram (ECG) - before treatment with stimulant drugs, a new American Heart Association statement recommends.The scientific statement on Cardiovascular Monitoring of Children and Adolescents with Heart Disease Receiving Stimulant Drugs is published online in Circulation: Journal of the American Heart Association.
Medication Improves Driving Ability ADHD Patients
The use of the medication methylphenidate considerably improves the driving ability of people with ADHD. This was shown in research done by Joris Verster of Utrecht University, The Netherlands. The study will appear in the May 2008 issue of Journal of Psychopharmacology.People with ADHD are often prescribed methylphenidate (brand name Ritalin) to counteract hyperactive behavior and attention dysfunction that may negatively affect their driving ability.
Stimulant Treatment For Young Children With ADHD Does Not Lead To Increased Risk Of Substance Abuse In Early Adulthood
Treatment of children with stimulant medications for attention-deficit/hyperactivity disorder (ADHD) does not increase the risk of substance abuse later in adolescence and early adulthood.
Encouraging Preschool Kids To Talk To Themselves
Parents should not worry when their pre-schoolers talk to themselves; in fact, they should encourage it, says Adam Winsler, an associate professor of psychology at George Mason University. His recent study published in Early Childhood Research Quarterly showed that 5-year-olds do better on motor tasks when they talk to themselves out loud (either spontaneously or when told to do so by an adult) than when they are silent.
Young Hyperactive Girls More Likely To Have Serious Problems As Adults
Young girls who are hyperactive are more likely to get hooked on smoking, under-perform in school or jobs and gravitate towards mentally abusive relationships as adults, according to a joint study by researchers from the Université de Montréal and the University College London (UCL).
Studying ADHD In Youth Of Different Races
The research in the article looked at childhood ADHD in underrepresented minorities, reviewing controversy around evaluation, diagnosis, and obstacles faced by families, ending with recommendations for assessment and treatment.
Increased Risk For Eating Disorders Found In Adolescent Girls With ADHD
Girls with attention deficit hyperactivity disorder stand a substantially greater risk of developing eating disorders in adolescence than girls without ADHD, a new study has found."Adolescent girls with ADHD frequently develop body-image dissatisfaction and may go through repeating cycles of binge eating and purging behaviors that are common in bulimia nervosa," said University of Virginia psychologist Amori Yee Mikami, who led the study.
ADHD Treatment For Children Different Between Specialties, Australia
Standardisation of diagnosis and treatment of ADHD is needed to ensure consistency between treatment by psychiatrists and paediatricians, according to a study in the latest Medical Journal of Australia.
Auriga Laboratories Announces FDA Approval Of Liquadd (TM) Oral Solution For The Treatment Of ADHD And Upcoming Product Launch
Auriga Laboratories, Inc. (OTCBB: ARGA), a specialty pharmaceutical company, announced today the FDA approval of Liquadd™ (dextroamphetamine sulfate) Oral Solution 5 mg/5 mL indicated for the treatment of Attention Deficit Disorder with Hyperactivity (ADHD). The ADHD market is valued at over $3.5 billion dollars, with approximately 35 million prescriptions written annually. Dextroamphetamine is one of the most frequently prescribed molecules for the treatment of ADHD.
